California-headquartered CDD provides web-based software that organises preclinical data into a searchable resource designed to help scientists “archive, mine and collaborate [on]” drug discovery data.
The firm maintains a database of over one million compounds gathered from public resources, researchers, scientific literature and leading vendors.
Subscribers to CDD’s service can access the dataset and, CDD claims, improve the efficiency of candidate screening.
Under the new collaboration ChemBridge, a discovery chemistry firm also based in California, has allowed CDD to include 10 of its most popular libraries, including its Diverset and CNS-Set collections, in its pre-clinical database.
In total more than 600,000 small molecules have been added to the CDD dataset as a result of the deal.
ChemBridge’s executive director, Duncan Beniston, said that part of the motivation was the deal was the recognition that a number of the firm’s development customers are already using CDD’s software.
He explained that: “Knowing that a number of our client companies and research organisations are actively using [it] we wanted to ensure [they] could easily integrate ChemBridge screening library data into their workflow.”
“Lots of data from lots of collaborations”
CDD CEO Barry Bunin welcomed the additional ChemBridge data and stressed the collaborative research advantages of his company’s web platform.
Dr Bunin suggested that all researchers “benefit when valuable new molecules and data are added to the database, [including] the latest compounds available right off the shelf from ChemBridge.”
He went on to say that CDD’s technology allows scientists to “view whole libraries and drill down to individual compounds and multiple data feeds,” adding that “it is a new way of simultaneously interacting with lots of data from lots of collaborations.”